SU2C is proud to announce its first Innovative Research Grant recipients.

The Children's Oncology Group on the difference between pediatric and adult cancer and where pediatric cancer research stands today.

The SU2C Dream Teams describe their projects and their hopes for the future of cancer research.

We’re thrilled to announce that our Scientific Advisory Committee has selected its first round of grant recipients. And we think you’ll find the science behind their projects as exciting and inspiring as we do.

"We're currently testing a new treatment for women whose ovarian cancer has recurred or progressed either during or shortly after chemotherapy treatment: a live, infectious virus."

"The reality is that somewhere around 3% to 4% of patients with cancer participate in clinical trials, while somewhere between 20% to 40% of all cancer patients could be eligible. Which means that the pace of getting answers to our questions is remarkably slower than it should be."

"An informed patient is his or her own best champion. In the performing arts, the saying goes that the best actors are the best listeners; in medicine, too, listening is one of the most important skills."

What do you do when your doctor diagnoses an inoperable tumor?

If you have a family history of cancer, genetic testing can reveal whether you have an inherited susceptibility to the disease. But how do you decide if it's the right choice for you?

According to the President of the Dana Farber Cancer Institute, we may soon look at the concept of “organ-based” cancer types as ancient history.

SU2C gets its message across with the help of lots and lots of statistics. Here's a complete list of facts and figures used in the big show. We cited them for you so you don't have to go searching for them. (You're welcome.)

How is the fight against childhood cancer going? Ask a family who has lost their child to cancer, and they will tell you just how much we have to learn.

Though cancer mortality rates are declining, the statistics hide a disturbing trend: the black-white mortality gap continues to grow.

SU2C's Cat Vasko gives a few good reasons to participate in breast cancer screening.

An exclusive sneak peek at David Servan-Schreiber’s groundbreaking book on how to help activate the body’s natural cancer fighting capacities.

Why do some patients benefit from a course of therapy while others don’t? And how do we tailor therapies to optimize their effects against cancer cells while steering clear of healthy cells and tissue?

At the heart of SU2C’s funding model is an emphasis on translational research. The majority of funds raised by the initiative will go to multidisciplinary “dream teams” collaborating on this type of research. But what exactly is it, and why is it so important?

An accessible explanation of what makes this devastating group of diseases tick.

What's on the horizon and within our grasp in cancer research, including nanoparticles, epigenetics and biomarkers.

The tumblers in nature's cosmic lock have aligned.